Ann: Change in substantial holding - Cannvalate, page-2

Very interesting to see the largest shareholder using their creep provision to increase their holdings up to 23%

Cannvalate of course with their deep connections to the company are a fantastic indicator that things are looking extremely promising for the upcoming clinical trial program. The entire clinical program is of course now fully funded as per the recent non-dilutive funding announcement of $38.5M through Clendon Biotech Fund.

To see a biotech funded through to Phase 3 trial and only sub 250M shares on issue is extremely rare

IRX is a hidden gem and this is a massive smoke signal - Cannvalate aren't buying on market (average 4.3cents represents nearly 50% premium to the current share price) if they don't see compelling value and excellent prospects for a return on their investment.

However, right now with very little promotion work put into it, IRX remains a complete unknown, so there is potential to get set at bargain basement prices. One has to wonder how long that opportunity will remain?

Seems like one of the best risk reward plays on the ASX to me. Good luck to all investors, both current and prospective.